Clinical pharmacology of nondopaminergic drugs in tourette syndrome

International Review of Neurobiology

Volumn 112, Issue , 2013, Pages 351-372

  Hartmann, Andreas ^a,b  

^a National Rare Disease Reference Center Gilles de la Tourette Syndrome   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

Author keywords

Alpha2 receptor agonists; Botulinum toxin; Cannabinoids; GABA agonists; Gilles de la Tourette syndrome; Immune modulation; Nicotine; Nondopaminergic drugs; Tetrabenazine; Tics

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CANNABINOID DERIVATIVE; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLONIDINE; DESIPRAMINE; DRONABINOL; ETIRACETAM; GUANFACINE; HALOPERIDOL; IMMUNOGLOBULIN; METHYLPHENIDATE; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NICOTINE; NICOTINE GUM; PLACEBO; RISPERIDONE; TETRABENAZINE; UNINDEXED DRUG;

ADD ON THERAPY; AKATHISIA; ALCOHOLISM; AROUSAL; ARTICLE; ATAXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BITTER TASTE; BRADYCARDIA; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; COHORT ANALYSIS; CONFUSION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSTONIA; ENDOCARDITIS; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GILLES DE LA TOURETTE SYNDROME; GLUTAMATERGIC NEUROTRANSMISSION; HEMIBALLISM; HICCUP; HISTAMINERGIC NEUROTRANSMISSION; HUMAN; HUNTINGTON CHOREA; HYPERACTIVITY; HYPERTENSION; HYPOTENSION; INSOMNIA; IRRITABILITY; MEMORY DISORDER; METABOLIC DISORDER; MORNING DOSAGE; MOTOR DYSFUNCTION; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PANIC; PARKINSONISM; PATHOPHYSIOLOGY; PHARYNGITIS; PLASMAPHERESIS; PREFRONTAL CORTEX; PRESCRIPTION; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SKIN IRRITATION; SPASTICITY; TARDIVE DYSKINESIA; TIC; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ALPHA2 RECEPTOR AGONISTS; BOTULINUM TOXIN; CANNABINOIDS; GABA AGONISTS; GILLES DE LA TOURETTE SYNDROME; IMMUNE MODULATION; NICOTINE; NONDOPAMINERGIC DRUGS; TETRABENAZINE; TICS;

ANIMALS; HUMANS; NEUROTRANSMITTER AGENTS; PHARMACOLOGY, CLINICAL; TOURETTE SYNDROME;

EID: 84888409949     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411546-0.00011-1     Document Type: Chapter

References (81)

1. Aliane V., Pérez S., Bohren Y., Deniau J.M., Kemel M.L. Key role of striatal cholinergic interneurons in processes leading to arrest of motor stereotypies. Brain 2011, 134:110-118.
2. Arnsten A.F. The use of alpha-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Review of Neurotherapeutics 2010, 10:1595-1605.
3. Awaad Y. Tics in Tourette syndrome: New treatment options. Journal of Child Neurology 1999, 14(5):316-319. PubMed PMID: 10342599.
4. Bloch M.H. Emerging treatments for Tourette's disorder. Current Psychiatry Reports 2008, 10:323-330.
5. Bloch M.H., Panza K.E., Landeros-Weisenberger A., Leckman J.F. Meta-analysis: Treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48:884-893.
6. Boon-yasidhi V., Kim Y.S., Scahill L. An open-label, prospective study of guanfacine in children with ADHD and tic disorders. Journal of the Medical Association of Thailand 2005, 88(Suppl. 8):S156-S162.
7. Cavanna A.E., Schrag A., Morley D., Orth M., Robertson M.M., Joyce E., et al. The Gilles de la Tourette syndrome-quality of life scale (GTS-QOL): Development and validation. Neurology 2008, 7:1410-1416.
8. Chappell P.B., Riddle M.A., Scahill L., Lynch K.A., Schultz R., Arnsten A., et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. Journal of the American Academy of Child and Adolescent Psychiatry 1995, 34:1140-1146.
9. Chen J.J., Ondo W.G., Dashtipour K., Swope D.M. Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clinical Therapeutics 2012, 34:1487-1504.
10. Cohen D.J., Detlor J., Young J.G., Shaywitz B.A. Clonidine ameliorates Gilles de la Tourette syndrome. Archives of General Psychiatry 1980, 37:1350-1357.
11. Cohen D.J., Young J.G., Nathanson J.A., Shaywitz B.A. Clonidine in Tourette's syndrome. Lancet 1979, 2:551-553.
12. Cubo E., Fernández Jaén A., Moreno C., Anaya B., González M., Kompoliti K. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: An 18-week, single-center, dose-escalating, prospective, open-label study. Clinical Therapeutics 2008, 30:182-189.
13. Cummings D.D., Singer H.S., Krieger M., Miller T.L., Mahone E.M. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: A pilot study. Clinical Neuropharmacology 2002, 25(6):325-332. PubMed PMID:12469007.
14. Curtis A., Clarke C.E., Rickards H.E. Cannabinoids for Tourette's Syndrome. Cochrane Database of Systematic Reviews 2009, 4. CD006565.
15. Daviss W.B., Patel N.C., Robb A.S., McDermott M.P., Bukstein O.G., Pelham W.E., et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. Journal of the American Academy of Child and Adolescent Psychiatry 2008, 47(2):189-198. PubMed PMID: 18182964. 10.1097/chi.0b013e31815d9ae4.
16. Du Y.S., Li H.F., Vance A., Zhong Y.Q., Jiao F.Y., Wang H.M., et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Australian and New Zealand Journal of Psychiatry 2008, 42:807-813.
17. Elamin I., Edwards M.J., Martino D. Immune dysfunction in Tourette syndrome. Behavioural Neurology 2013, 27:23-32.
18. Ercan-Sencicek A.G., Stillman A.A., Ghosh A.K., Bilguvar K., O'Roak B.J., Mason C.E., et al. L-histidine decarboxylase and Tourette's syndrome. The New England Journal of Medicine 2010, 362(20):1901-1908. Epub 2010 May 5. PubMed PMID: 20445167; PubMed Central PMCID: PMC2894694. 10.1056/NEJMoa0907006.
19. Fernandez T.V., Sanders S.J., Yurkiewicz I.R., Ercan-Sencicek A.G., Kim Y.S., Fishman D.O., et al. Rare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biological Psychiatry 2012, 71:392-402.
20. Fernández-Ruiz J., Hernández M., Ramos J.A. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neuroscience and Therapeutics 2010, 16:e72-e91.
21. Fras I. Guanfacine for Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1996, 35:3-4.
22. Gaffney G.R., Perry P.J., Lund B.C., Bever-Stille K.A., Arndt S., Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:330-336.
23. Garvey M.A., Perlmutter S.J., Allen A.J., Hamburger S., Lougee L., Leonard H.L., et al. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biological Psychiatry 1999, 45:1564-1571.
24. Gittis A.H., Leventhal D.K., Fensterheim B.A., Pettibone J.R., Berke J.D., Kreitzer A.C. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. Journal of Neuroscience 2011, 31:15727-15731.
25. Goetz C.G. Clonidine and clonazepam in Tourette syndrome. Advances in Neurology 1992, 58:245-251.
26. Goetz C.G., Tanner C.M., Wilson R.S., Carroll V.S., Como P.G., Shannon K.M. Clonidine and Gilles de la Tourette's syndrome: Double-blind study using objective rating methods. Annals of Neurology 1987, 21:307-310.
27. Goldberg J.A., Reynolds J.N. Spontaneous firing and evoked pauses in the tonically active cholinergic interneurons of the striatum. Neuroscience 2011, 198:27-43.
28. Gonce M., Barbeau A. Seven cases of Gilles de la Tourette's syndrome: Partial relief with clonazepam: A pilot study. Canadian Journal of Neurological Sciences 1977, 4:279-283.
29. Gulledge A.T., Park S.B., Kawaguchi Y., Stuart G.J. Heterogeneity of phasic cholinergic signaling in neocortical neurons. Journal of Neurophysiology 2007, 97:2215-2229.
30. Hartmann A., Worbe Y., Arnulf I. Increasing histamine neurotransmission in Gilles de la Tourette syndrome. Journal of Neurology 2011, 259:375-376.
31. Hedderick E.F., Morris C.M., Singer H.S. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatric Neurology 2009, 40:420-425.
32. Hoekstra P.J., Minderaa R.B., Kallenberg C.G. Lack of effect of intravenous immunoglobulins on tics: A double-blind placebo-controlled study. Journal of Clinical Psychiatry 2004, 65:537-542.
33. Hoopes S.P. Donepezil for Tourette's disorder and ADHD. Journal of Clinical Psychopharmacology 1999, 19(4):381-382. PubMed PMID: 10440471.
34. Jankovic J., Glaze D.G., Frost J.D. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984, 34:688-692.
35. Jankovic J., Kurlan R. Tourette syndrome: Evolving concepts. Movement Disorders 2011, 26:1149-1156.
36. Jankovic J., Kurlan R. Treatment of tics in patients with Tourette syndrome: Recommendations according to the European Society for the Study of Tourette Syndrome (author reply). Movement Disorders 2011, 26:2448.
37. Kalanithi P.S., Zheng W., Kataoka Y., DiFiglia M., Grantz H., Saper C.B., et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:13307-13312.
38. Kataoka Y., Kalanithi P.S., Grantz H., Schwartz M.L., Saper C., Leckman J.F., et al. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. Journal of Comparative Neurology 2010, 518:277-291.
39. King A., Harris P., Fritzell J., Kurlan R. Syncope in children with Tourette's syndrome treated with guanfacine. Movement Disorders 2006, 21:419-420.
40. Kuepper R., Morrison P.D., van Os J., Murray R.M., Kenis G., Henquet C. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophrenia Research 2010, 121:107-117.
41. Kwak C.H., Hanna P.A., Jankovic J. Botulinum toxin in the treatment of tics. Archives of Neurology 2000, 57:1190-1193.
42. Leckman J.F., Hardin M.T., Riddle M.A., Stevenson J., Ort S.I., Cohen D.J. Clonidine treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry 1991, 48:324-328.
43. Lichter D.G., Jackson L.A. Predictors of clonidine response in Tourette syndrome: Implications and inferences. Journal of Child Neurology 1996, 2:93-97.
44. Marras C., Andrews D., Sime E., Lang A.E. Botulinum toxin for simple motor tics: A randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605-610.
45. Martino D., Dale R.C., Gilbert D.L., Giovannoni G., Leckman J.F. Immunopathogenic mechanisms in Tourette syndrome: A critical review. Movement Disorders 2009, 24:1267-1279.
46. McConville B.J., Sanberg P.R., Fogelson M.H., King J., Cirino P., Parker K.W., et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biological Psychiatry 1992, 31:832-840.
47. Müller-Vahl K.R. Surgical treatment of Tourette syndrome. Neuroscience and Biobehavioral Reviews 2013, 37(6):1178-1185. Epub 2012 Oct 4. PubMed PMID: 23041074. 10.1016/j.neubiorev.2012.09.012.
48. Müller-Vahl K.R., Krueger D. Does Tourette syndrome prevent tardive dyskinesia?. Movement Disorders 2011, 26:2442-2443.
49. Müller-Vahl K.R., Prevedel H., Theloe K., Kolbe H., Emrich H.M., Schneider U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): No influence on neuropsychological performance. Neuropsychopharmacology 2003, 28:384-388.
50. Müller-Vahl K.R., Roessner V., European Society for the Study of Tourette Syndrome Treatment of tics in patients with Tourette syndrome: Recommendations according to the European Society for the Study of Tourette Syndrome. Movement Disorders 2011, 26:2447.
51. Müller-Vahl K.R., Schneider U., Koblenz A., Jöbges M., Kolbe H., Daldrup T., et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry 2002, 35:57-61.
52. Müller-Vahl K.R., Schneider U., Prevedel H., Theloe K., Kolbe H., Daldrup T., et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. Journal of Clinical Psychiatry 2003, 64:459-465.
53. Niederhofer H. Donepezil also effective in the treatment of Tourette's syndrome?. Movement Disorders 2006, 21:2027.
54. Ondo W.G., Jong D., Davis A. Comparison of weight gain in treatments for Tourette syndrome: Tetrabenazine versus neuroleptic drugs. Journal of Child Neurology 2008, 23:435-437.
55. Perlmutter S.J., Leitman S.F., Garvey M.A., Hamburger S., Feldman E., Leonard H.L., et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153-1158.
56. Porta M., Maggioni G., Ottaviani F., Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurological Sciences 2004, 24:420-423.
57. Porta M., Sassi M., Cavallazzi M., Fornari M., Brambilla A., Servello D. Tourette's syndrome and role of tetrabenazine: Review and personal experience. Clinical Drug Investigation 2008, 28:443-459.
58. Pringsheim T., Doja A., Gorman D., McKinlay D., Day L., Billinghurst L., et al. Canadian guidelines for the evidence-based treatment of tic disorders: Pharmacotherapy. Canadian Journal of Psychiatry 2012, 57:133-143.
59. Pringsheim T., Pearce M. Complications of antipsychotic therapy in children with Tourette syndrome. Pediatric Neurology 2010, 43:17-20.
60. Rath J.J., Tavy D.L., Wertenbroek A.A., van Woerkom T.C., de Bruijn S.F. Botulinum toxin type A in simple motor tics: Short-term and long-term treatment-effects. Parkinsonism & Related Disorders 2010, 16:478-481.
61. Rickards H., Cavanna A.E., Worrall R. Treatment practices in Tourette syndrome: The European perspective. European Journal of Paediatric Neurology 2012, 16:361-364.
62. Sanberg P.R., McConville B.J., Fogelson H.M., Manderscheid P.Z., Parker K.W., Blythe M.M., et al. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomedicine & Pharmacotherapy 1989, 43:19-23.
63. Sandor P. Pharmacological management of tics in patients with TS. Journal of Psychosomatic Research 2003, 55(1):41-48. Review. PubMed PMID: 12842230.
64. Scahill L., Aman M.G., McDougle C.J., McCracken J.T., Tierney E., Dziura J., et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 2006, 16(5):589-598. PubMed PMID: 17069547.
65. Scahill L., Chappell P.B., Kim Y.S., Schultz R.T., Katsovich L., Shepherd E., et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry 2001, 158:1067-1074.
66. Scott B.L., Jankovic J., Donovan D.T. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Movement Disorders 1996, 11:431-433.
67. Shapiro A.K., Shapiro E., Eisenkraft G.J. Treatment of Gilles de la Tourette's syndrome with clonidine and neuroleptics. Archives of General Psychiatry 1983, 40:1235-1240.
68. Silver A.A., Shytle R.D., Philipp M.K., Wilkinson B.J., McConville B., Sanberg P.R. Transdermal nicotine and haloperidol in Tourette's disorder: A double-blind placebo-controlled study. Journal of Clinical Psychiatry 2001, 62:707-714.
69. Singer H.S., Morris C., Grados M. Glutamatergic modulatory therapy for Tourette syndrome. Medical Hypotheses 2010, 74:862-867.
70. Singer H.S., Wendlandt J., Krieger M., Giuliano J. Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599-604.
71. Singh S.K., Jankovic J. Tardive dystonia in patients with Tourette's syndrome. Movement Disorders 1988, 3:274-280.
72. Skerritt J.H., Johnston G.A. Enhancement of GABA binding by benzodiazepines and related anxiolytics. European Journal of Pharmacology 1983, 89:193-198.
73. Stahl S.M., Berger P.A. Physostigmine in Tourette syndrome: Evidence for cholinergic underactivity. American Journal of Psychiatry 1981, 138:240-242.
74. Steingard R.J., Goldberg M., Lee D., DeMaso D.R. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 1994, 33:394-399.
75. Sulzer D., Joyce M.P., Lin L., Geldwert D., Haber S.N., Hattori T., et al. Dopamine neurons make glutamatergic synapses in vitro. Journal of Neuroscience 1998, 18:4588-4602.
76. Swedo S.E., Leonard H.L., Garvey M., Mittleman B., Allen A.J., Perlmutter S., et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: Clinical description of the first 50 cases. American Journal of Psychiatry 1998, 155:264-271.
77. Tanner C.M., Goetz C.G., Klawans H.L. Cholinergic mechanisms in Tourette syndrome. Neurology 1982, 32:1315-1317.
78. Tourette's Syndrome Study Group Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 2002, 58:527-536.
79. Trimble M.R., Whurr R., Brookes G., Robertson M.M. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Movement Disorders 1998, 13(3):617-619. PubMed PMID: 9613771.
80. van de Griendt J.M., Verdellen C.W., van Dijk M.K., Verbraak M.J. Behavioural treatment of tics: Habit reversal and exposure with response prevention. Neuroscience and Biobehavioral Reviews 2013, 37(6):1172-1177. Epub 2012 Oct 23. PubMed PMID: 23089154. 10.1016/j.neubiorev.2012.10.007.
81. Weisman H., Qureshi I.A., Leckman J.F., Scahill L., Bloch M.H. Systematic review: Pharmacological treatment of tic disorders-Efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neuroscience and Biobehavioral Reviews 2012, 37:1162-1171. pii: S0149-7634(12)00161-3. 10.1016/j.neubiorev.2012.09.008.